Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

07-12-2020 | Original Article | Uitgave 4/2021 Open Access

Netherlands Heart Journal 4/2021

The Coronary Sinus Reducer; 5-year Dutch experience

Tijdschrift:
Netherlands Heart Journal > Uitgave 4/2021
Auteurs:
M. J. M. Silvis, M. Dekker, C. Zivelonghi, P. Agostoni, P. R. Stella, P. A. Doevendans, D. P. V. de Kleijn, J. P. van Kuijk, G. E. Leenders, L. Timmers
Belangrijke opmerkingen

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s12471-020-01525-8) contains supplementary material, which is available to authorized users.
The authors M.J.M. Silvis and M. Dekker contributed equally to this manuscript.

Abstract

Background

Refractory angina is a growing and major health-care problem affecting millions of patients with coronary artery disease worldwide. The Coronary Sinus Reducer (CSR) is a device that may be considered for the relief of symptoms of refractory angina. It causes increased venous pressure leading to a dilatation of arterioles and reduced arterial vascular resistance in the sub-endocardium. This study describes the 5‑year Dutch experience regarding safety and efficacy of the CSR.

Methods

One hundred and thirty-two patients with refractory angina were treated with the CSR. The primary efficacy endpoint of the study was Canadian Cardiovascular Society (CCS) class improvement between baseline and 6‑month follow-up. The primary safety endpoint was successful CSR implantation in the absence of any device-related events.

Results

Eighty-five patients (67%) showed improvement of at least 1 CCS class and 43 patients (34%) of at least 2 classes. Mean CCS class improved from 3.17 ± 0.61 to 2.12 ± 1.07 after implantation (P < 0.001). The CSR was successfully implanted in 99% of the patients and only minor complications during implantation were reported.

Conclusion

The CSR is a simple, safe, and effective option for most patients with refractory angina. However, approximately thirty percent of the patients showed no benefit after implantation. Future studies should focus on the exact underlying mechanisms of action and reasons for non-response to better identify patients that could benefit most from this therapy.

Onze productaanbevelingen

Netherlands Heart Journal

Het Netherlands Heart Journal wordt uitgegeven in samenwerking met de Nederlandse Vereniging voor Cardiologie en de Nederlandse Hartstichting. Het tijdschrift is Engelstalig en wordt gratis beschikbaa ...

Extra materiaal
Literatuur
Over dit artikel

Andere artikelen Uitgave 4/2021

Netherlands Heart Journal 4/2021 Naar de uitgave